The Canadian Agency for Drugs and Technologies in Health (CADTH) has published a review of clinical and cost effectiveness on the use of cannabinoids for the management of neuropathic pain. The review concludes that: “Overall, the limited evidence suggests that cannabinoids may provide pain relief in patients with HIV or multiple sclerosis (MS) who have neuropathic pain when used as add on therapy. It is not clear if this benefit would be maintained longer-term. No benefit was observed in diabetic neuropathy and pain relief with nabilone was inferior to a narcotic analgesic. These points may be considered when making formulary decisions about the use of cannabinoids in neuropathic pain.”